Newsroom | 1355 results

IRVINE, Calif.--(BUSINESS WIRE)--Dr. Young brings an extraordinary depth of experience in vaccine science, immunology, and pharmaceutical development, with more than 40 years of leadership across academia, government initiatives, and the biotechnology industry. He has been a driving force in advancing vaccine innovation, regulatory strategy, and global health impact. He was involved in the Operation Warp Speed effort, the U.S. government’s coordinated initiative to accelerate the development, m...

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts the...

SEATTLE--(BUSINESS WIRE)--Access to Advanced Health Institute (AAHI), a global leader in translating high-impact science into scalable, field-ready vaccine solutions, today announced an exciting new partnership with Quratis, a premier biotechnology company and advanced Contract Development and Manufacturing Organization (CDMO). This collaboration marks a pivotal step forward in breaking through barriers in global health equity around the world. Under this strategic alliance, Quratis has been se...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Cantor Global Healthcare Conference on Wednesday, September 3 at 11:30 AM Eastern Time Wells Fargo Healthcare Conference on Thursday, September 4 at 11:00 AM Eastern Time Morgan Stanley Annual Global Healthcare Conference on Tuesday, September 9 at 10:45 AM Eastern Time Baird Global Healthcare Conference on Wednesday, September 10...

DUBLIN--(BUSINESS WIRE)--The "mRNA Platform - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for mRNA Platform was estimated at US$152.0 Billion in 2024 and is projected to reach US$129.1 Billion by 2030, growing at a CAGR of -2.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The mRNA platform has emerged as a grou...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, announced today that it has filed suit in the Unified Patent Court (UPC) of the European Union against Pfizer Inc. and certain of its subsidiaries (action number 35071/2025), seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the ’26...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the opening of a new Phase 2 study to assess the BioShield™ platform, anchored by ANKTIVA® (nogapendekin alfa inbakicept-pmln), in patients with long COVID. An estimated one in five Americans with a previous COVID-19 infection has long COVID, which is comprised of a broad range of symptoms that can substantially impact a patient’s quality of life. Long COVID remains a signifi...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced its financial results for the second quarter ended June 30, 2025, and provided corporate updates. “The Company continues to advance and provide meaningful clinical data across our mRNA therapeutics and vaccines pipeline,...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2025 and reaffirmed its 2025 Revenue guidance while raising guidance(1) for Adjusted(2) diluted EPS. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “Pfizer had another strong quarter of focused execution and we’re pleased with our progress in advancing our R&D pipeline, driving our commercial performance and expanding our margins. We continue to strengthen our company...

ANN ARBOR, Mich.--(BUSINESS WIRE)--Long Covid patients around the U.S. looking to participate in a clinical trial from home can sign up to be notified when an upcoming study conducted by scientists at Scripps Research and supported by the Schmidt Initiative for Long Covid (SILC) opens. Patients can sign up on the Long Covid Treatment Trial (LoCITT) website. The upcoming study, powered by the MyDataHelps platform from CareEvolution, is a fully remote clinical trial investigating the efficacy of...